OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

Clear
Clear
Clear
Clear
Clear
Clear
Clear
Investigator: Roger Bullock

1 Projects | 1 Researchers | $1,500,000 Invested

2018

Oryzon Genomics S.A.

Roger Bullock, PhD, BA, MA

ETHERAL : Epigenetic THERapy in ALzheimer’s Disease . A multicenter, multinational, randomized, double-blind, placebo-controlled, 3-arm, 26 weeks parallel-group study to evaluate the safety, tolerability of ORY-2001 in patients with mild-moderate AD

  • Funding Amount: $1,500,000
  • Organization Type: Biotechnology/For Profit
  • Program: Clinical
  • Target: Epigenetics
  • Status: Closed